Scolaris Content Display Scolaris Content Display

Prophylactic platelet transfusions prior to surgery for people with a low platelet count

This is not the most recent version

Appendices

Appendix 1. CENTRAL (the Cochrane Library)

#1 MeSH descriptor: [Blood Platelets] explode all trees
#2 transfus*
#3 #1 and #2
#4 MeSH descriptor: [Platelet Transfusion] explode all trees
#5 MeSH descriptor: [Plateletpheresis] explode all trees
#6 ((platelet* or thrombocyte*) near/5 (prophyla* or transfus* or infus* or administ* or requir* or need* or product or products or component* or concentrate* or apheres* or pooled or single donor* or random donor*))
#7 thrombo?ytopheres* or plateletpheres*
#8 ((platelet* or thrombocyte*) near/5 (protocol* or trigger* or threshold* or schedul* or dose* or dosing or usage or utilisation or utilization))
#9 #3 or #4 or #5 or #6 or #7 or #8
#10 MeSH descriptor: [Specialties, Surgical] explode all trees
#11 MeSH descriptor: [Surgical Procedures, Operative] explode all trees
#12 MeSH descriptor: [Perioperative Care] explode all trees
#13 MeSH descriptor: [Perioperative Period] explode all trees
#14 surg* or presurg* or postsurg* or operat* or preoperat* or perioperat* or postoperat* or transplant* or bypass* or
arthroplasty or neurosurg*
#15 #10 or #11 or #12 or #13 or #14
#16 #9 and #15

Appendix 2. MEDLINE (OvidSP)

1. Platelet Transfusion/
2. Plateletpheresis/
3. Blood Platelets/ and transfus*.mp.
4. ((platelet* or thrombocyte*) adj5 (prophyla* or transfus* or infus* or administ* or requir* or need* or product* or component* or concentrate* or apheres* or pooled or single donor or random donor)).tw,kf.
5. (thromboc?topheres* or plateletpheres*).tw,kf.
6. ((platelet* or thrombocyte*) adj5 (protocol* or trigger* or threshold* or schedul* or dose* or dosing or usage or utili?ation)).tw,kf.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Perioperative Care/
9. exp Surgical Procedures, Operative/
10. exp Perioperative Period/
11. exp Specialties, Surgical/
12. (preoperat* or postoperat* or perioperat* or operat* or surg* or presurg* or postsurg* or perisurg* or transplant* or bypass* or arthroplasty or neurosurg*).mp.
13. 8 or 9 or 10 or 11 or 12
14. 7 and 13
15. Meta‐Analysis.pt.
16. ((meta analy* or metaanaly*) and (trials or studies)).ab.
17. (meta analy* or metaanaly* or evidence‐based).ti.
18. ((systematic* or evidence‐based) adj2 (review* or overview*)).tw.
19. (cochrane or medline or pubmed or embase or cinahl or cinhal or lilacs or "web of science" or science citation index or scopus or search terms or literature search or electronic search* or comprehensive search* or systematic search* or published articles or search strateg* or reference list* or bibliograph* or handsearch* or hand search* or manual* search*).ab.
20. Cochrane Database of systematic reviews.jn.
21. (additional adj (papers or articles or sources)).ab.
22. ((electronic* or online) adj (sources or resources or databases)).ab.
23. (relevant adj (journals or articles)).ab.
24. or/15‐23
25. Review.pt.
26. RANDOMIZED CONTROLLED TRIALS AS TOPIC/
27. selection criteria.ab. or critical appraisal.ti.
28. (data adj (abstraction or extraction or analys*)).ab.
29. RANDOMIZED CONTROLLED TRIAL/
30. or/26‐29
31. 25 and 30
32. 24 or 31
33. exp CONTROLLED CLINICAL TRIAL/
34. exp CONTROLLED CLINICAL TRIALS AS TOPIC/
35. (randomi* or trial).tw,kf.
36. (placebo or randomly or groups).ab.
37. or/33‐36
38. CONTROLLED BEFORE‐AFTER STUDIES/
39. INTERRUPTED TIME SERIES ANALYSIS/
40. (nonrandom* or non random*).tw,kf.
41. (pre‐post or pre‐test* or pretest* or posttest* or post‐test* or (pre adj5 post)).tw,kf.
42. (controlled clinical study or controlled study or control group*).tw,kf.
43. ((before adj3 after) or "before‐after" or interrupted time series or time point* or repeated measur*).tw,kf.
44. 37 or 38 or 39 or 40 or 41 or 42 or 43
45. 32 or 37 or 44
46. (ANIMALS/ or exp ANIMAL EXPERIMENTATION/ or exp MODELS, ANIMAL/) not HUMANS/
47. Editorial.pt.
48. 46 or 47
49. 45 not 48
50. 14 and 49

Appendix 3. PubMed (epublications ahead of print only)

#1 ((platelet* OR thrombocyte*) AND (prophyla* OR transfus* OR infus* OR administ* OR requir* OR need* OR product*OR component* OR concentrate* OR apheres* OR pooled OR single donor OR "random donor" OR "random donors" OR protocol* OR trigger* OR threshold* OR schedul* OR dose* OR dosing OR usage OR utilisation OR utilization))
#2 (thrombo?ytopheres* OR plateletpheres*)
#3 #1 OR #2
#4 (preoperat*[TI] OR postoperat*[TI] OR perioperat*[TI] OR operation[TI] OR operations[TI] OR operating[TI] OR operated[TI] OR surgery[TI] OR surgical*[TI] OR presurg*[TI] OR postsurg*[TI] OR perisurg*[TI] OR transplant[TI] OR transplants[TI] OR transplanted[TI] OR transplanting[TI] OR transplantation*[TI] OR bypass*[TI] OR arthroplasty*[TI] OR neurosurg*[TI])
#5 #3 AND #4
#6 ((random* OR blind* OR "control group" OR placebo OR "controlled trial" OR "controlled study" OR groups OR trials OR "systematic review" OR "systematic overview" OR "meta‐analysis" OR metaanalysis OR "literature search" OR medline OR cochrane OR embase OR "time series" OR "repeated measures" OR "before and after" OR "before‐after" OR "pre‐test" OR "post‐test" OR pretest* OR posttest*) AND (publisher[sb] OR inprocess[sb] OR pubmednotmedline[sb]))
#7 #5 AND #6

Appendix 4. Embase (OvidSP)

1. Thrombocyte Transfusion/
2. Thrombocyte/ and transfus*.mp.
3. *Thrombocyte/
4. Thrombo?ytopheresis/
5. ((platelet* or thrombocyte*) adj5 (prophyla* or transfus* or infus* or administ* or requir* or need* or product* or
component* or concentrate* or apheres* or pooled or single donor or random donor)).tw.
6. (thrombo?ytopheres* or plateletpheres*).tw.
7. ((platelet* or thrombocyte*) adj5 (protocol* or trigger* or threshold* or schedul* or dose* or dosing or usage or utili?ation)).tw.
8. or/1‐7
9. exp Surgery/
10. (preoperat* or postoperat* or perioperat* or operati* or surg* or presurg* or postsurg* or perisurg* or transplant* or bypass* or arthroplasty or neurosurg*).mp.
11. 9 or 10
12. 8 and 11
13. Meta Analysis/
14. Systematic Review/
15. (meta analy* or metaanalys*).tw.
16. ((systematic* or literature) adj2 (review* or overview* or search*)).tw.
17. (cochrane or embase or cinahl or cinhal or lilacs or BIDS or science citation index or psyclit or psychlit or psycinfo or psychinfo or cancerlit).ti,ab.
18. ((electronic* or online) adj (sources or resources or databases)).ab.
19. (additional adj (articles or papers or sources)).ab.
20. (reference lists or bibliograph* or handsearch* or hand search* or manual* search*).ab.
21. (relevant adj (journals or articles)).ab.
22. (search term* or published articles or search strateg*).ab.
23. or/13‐22
24. (data extraction or selection criteria).ab.
25. review.pt.
26. 23 or (24 and 25)
27. editorial.pt.
28. 26 not 27
29. randomized controlled trial/ or crossover‐procedure/ or single‐blind procedure/ or double‐blind procedure/ or triple‐blind procedure/
30. (random* or factorial* or crossover* or cross over* or cross‐over* or placebo* or doubl* blind* or singl* blind* or tripl* blind* or assign* or allocat*).tw.
31. (nonrandom* or non random*).tw.
32. (controlled clinical study or controlled study or control group* or trial).tw.
33. controlled clinical trial/
34. time series analysis/
35. epidemiology/
36. pretest posttest control group design/ or pretest posttest design/
37. (pre‐post or pre‐test* or pretest* or posttest* or post‐test* or (pre adj5 post)).tw.
38. ((before adj3 after) or "before‐after" or interrupted time series or time point* or repeated measur*).tw.
39. or/28‐38
40. 12 and 39
41. Animal experiment/ not (human experiment/ or human/)
42. 40 not 41
43. limit 42 to embase

Appendix 5. CINAHL (EBSCOHost)

S1 (MH "Blood Platelets")
S2 TX transfus*
S3 S1 AND S2
S4 (MH "Platelet Transfusion")
S5 (MH "Plateletpheresis")
S6 TX ((platelet* or thrombocyte*) N5 (prophyla* or transfus* or infus* or administ* or requir* or need* or product or products or component* or concentrate* or apheres* or pooled or single donor* or random donor*))
S7 TX thrombocytopheres* or plateletpheres*
S8 TX ((platelet* or thrombocyte*) N5 (protocol* or trigger* or threshold* or schedul* or dose* or dosing or usage or utilisation or utilization))
S9 S3 OR S4 OR S5 OR S6 OR S7 OR S8
S10 (MH "Specialties, Surgical+")
S11 (MH "Surgery, Operative+")
S12 (MH "Perioperative Care+")
S13 TX (surg* or presurg* or postsurg* or operat* or preoperat* or perioperat* or postoperat* or transplant* or bypass* or arthroplasty or neurosurg*)
S14 S10 OR S11 OR S12 OR S13
S15 S9 AND S14
S16 (MH Clinical Trials+)
S17 PT Clinical Trial
S18 TI ((controlled trial*) or (clinical trial*)) OR AB ((controlled trial*) or (clinical trial*))
S19 TI ((singl* blind*) OR (doubl* blind*) OR (trebl* blind*) OR (tripl* blind*) OR (singl* mask*) OR (doubl* mask*) OR (tripl* mask*)) OR AB ((singl* blind*) OR (doubl* blind*) OR (trebl* blind*) OR (tripl* blind*) OR (singl* mask*) OR (doubl* mask*) OR (tripl* mask*))
S20 TI randomi* OR AB randomi*
S21 MH RANDOM ASSIGNMENT
S22 TI ((phase three) or (phase III)) or AB ((phase three) or (phase III) or (phase three))
S23 ( TI (random* N2 (assign* or allocat*)) ) OR ( AB (random* N2 (assign* or allocat*)) )
S24 MH PLACEBOS
S25 MH META ANALYSIS
S26 MH SYSTEMATIC REVIEW
S27 TI ("meta analys*" OR metaanalys* OR "systematic review" OR "systematic overview" OR "systematic search*") OR AB ("meta analys*" OR metaanalys* OR "systematic review" OR "systematic overview" OR "systematic search*")
S28 TI ("literature review" OR "literature overview" OR "literature search*") OR AB ("literature review" OR "literature overview" OR "literature search*")
S29 TI (cochrane OR embase OR cinahl OR cinhal OR lilacs OR BIDS OR science AND citation AND index OR cancerlit) OR AB (cochrane OR embase OR cinahl OR cinhal OR lilacs OR BIDS OR science AND citation AND index OR cancerlit)
S30 TI placebo* OR AB placebo*
S31 MH QUANTITATIVE STUDIES
S32 S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31
S33 (MH "Controlled Before‐After Studies") OR (MH "Interrupted Time Series Analysis") OR (MH "Nonrandomized Trials") OR (MH "Pretest‐Posttest Design+")
S34 (MH "Quasi‐Experimental Studies+") OR (MH "Repeated Measures")
S35 TX (nonrandom* or non random*)
S36 TX (pre‐post or pre‐test* or pretest* or posttest* or post‐test* or (pre N5 post))
S37 TX (controlled clinical study or controlled study or control group*)
S38 TX ((before N3 after) or "before‐after" or interrupted time series or time point* or repeated measur*)
S39 S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38
S40 S15 AND S39

Appendix 6. Transfusion Evidence Library

Clinical Specialty: Surgery
Subject Area: Blood Components/Platelets

Appendix 7. LILACS

tw:((platelet OR platelets) AND (prophylactic OR prophylaxis OR transfusion OR transfused OR transfusing OR infused OR infusion OR administered OR required OR needed OR product OR component OR concentrate OR concentrates OR apheresis OR pooled OR donor OR donors OR protocol OR trigger OR threshold OR schedule OR dose OR doses OR dosing OR usage OR utilisation OR utilization)) AND (instance:"regional") AND ( db:("LILACS") AND type_of_study:("clinical_trials"))

Appendix 8. WEB OF SCIENCE CPC‐IS

#1 TS=((platelet* or thrombocyte*) NEAR/5 (prophyla* or transfus* or infus* or administ* or requir* or need* or product or products or component* or concentrate* or apheres* or pooled or donor*))
#2 TS=(thrombocytopheres* or plateletpheres*)
#3 TS=((platelet* or thrombocyte*) NEAR/5 (protocol* or trigger* or threshold* or schedul* or dose* or dosing or usage or utilisation or utilization))
#4 #3 OR #2 OR #1
#5 TS=(surg* or presurg* or postsurg* or operat* or preoperat* or perioperat* or postoperat* or transplant* or bypass* or arthroplasty or neurosurg*)
#6 #5 AND #4
#7 TS=(random* OR blind* OR "control group" OR placebo OR "controlled trial" OR "controlled study" OR groups OR trials OR "systematic review" OR "systematic overview" OR "meta‐analysis" OR metaanalysis OR "literature search" OR medline OR cochrane OR embase OR "time series" OR "repeated measures" OR "before and after" OR "before‐after" OR "pre‐test" OR "post‐test" OR pretest* OR posttest*)
#8 #7 AND #6

Appendix 9. ClinicalTrials.gov

Search Terms: (preoperative OR postoperative OR perioperative OR operation OR surgery OR presurgery OR postsurgery OR presurgical OR postsurgical OR transplantation OR bypass OR arthroplasty OR neurosurgery) AND (platelet transfusion OR platelet concentrate)
OR
Search Terms: (preoperative OR postoperative OR perioperative OR operation OR surgery OR presurgery OR postsurgery OR presurgical OR postsurgical OR transplantation OR bypass OR arthroplasty OR neurosurgery)
Interventions: platelet transfusion OR platelet concentrate OR prophylactic platelets

Appendix 10. WHO ICTRP

Title: platelet transfusion OR platelet concentrate
Recruitment Status: ALL
OR
Title: preoperative OR postoperative OR perioperative OR operation OR surgery OR surgical OR presurgery OR postsurgery OR presurgical OR postsurgical OR perisurgical OR transplant OR transplantation OR bypass OR arthroplasty OR neurosurgery
Intervention: platelets OR platelet transfusion OR platelet concentrate OR platelet concentrates
Recruitment Status: ALL

Appendix 11. ROBINS‐I

ROBINS‐I tool (Stage I)

Specify the review question

Participants

People of all ages with a low platelet count who are due to have surgery

Experimental intervention 1

Prophylactic platelet transfusion before surgery

Control intervention 1

No Prophylactic platelet transfusion before surgery

Control intervention 2

Artificial platelet substitutes for example lyophilised platelets, infusible plasma membranes and liposomes with inserted platelet receptors

Control intervention 3

Cryosupernatant

Control intervention 4

Thrombopoietin (TPO) mimetics

Control intervention 5

Antifibrinolytic drugs

Outcomes

Primary outcomes

  • Mortality (all‐causes, secondary to bleeding, secondary to thromboembolism and secondary to infection) within 30 days and 90 days of surgery.

  • The number of participants with major procedure‐related bleeding within 7 days of surgery, defined as:

    • Surgical site bleeding requiring a second intervention or reoperation or surgical site bleeding that causes a haematoma or haemarthrosis of sufficient size to delay mobilisation or wound healing,

    • Bleeding of sufficient size to cause delayed wound healing, or wound infection or surgical site bleeding that is unexpected and prolonged or causes haemodynamic instability (as defined by the study) that is associated with a 20g/L drop in Hb

    • Bleeding that requires two or more units of whole blood/red cells within 24h of the bleeding

    • Bleeding that defined by the study with no further details

Secondary outcomes

  • The number of participants with minor procedure‐related bleeding within 7 days of surgery (e.g. haematoma, prolonged bleeding at surgical site that does not fulfil the definition for major bleeding)

  • Number of platelet transfusions per participant and number of platelet components per participant

  • Number of red cell transfusions per participant and number of red cell components per participant

  • Proportion of participants requiring additional interventions to stop bleeding (surgical, medical e.g. tranexamic acid, other blood products e.g. fresh frozen plasma (FFP), cryoprecipitate, fibrinogen) within 7 days from the surgery

  • Quality of life assessment using validated tools

  • Serious adverse events due to:Transfusion (transfusion reactions, transfusion‐related acute lung injury (TRALI), transfusion related infection, transfusion‐associated circulatory overload (TACO), transfusion‐related dyspnoea) within 24 hours of the transfusion

  • Surgery (e.g. delayed wound healing, infection) within 30 days after the operation;Length of hospital stay and length of ITU stay

  • Venous and arterial thromboembolism (including deep vein thrombosis; pulmonary embolism; stroke; myocardial infarction)

List the confounding areas relevant to all or most studies

We have pre‐specified the main potential confounding factors.

  • Age ( (neonate, child (aged one to 15 years), adult (aged 16 years or older))

  • Gender: male:female ratio

  • Underlying conditions which caused thrombocytopenia

  • Minor surgery or major surgery

  • Severity of thrombocytopaenia

  • Haemodynamic status at baseline

  • Participants with clotting abnormalities, such as disseminated intravascular coagulation (DIC), or concomitant use of anticoagulant or antiplatelet agents

  • Previous severe bleeding (e.g. World Health Organization (WHO) grade 3 or 4 or equivalent)

List the possible co‐interventions that could be different between intervention groups and could have an impact on outcomes

We have pre‐specified the possible co‐interventions that could be different between intervention groups and could have an impact on outcomes.

  • Receiving corticosteroids

  • Intravenous immunoglobulin (IVIG) which usually is given when thrombocytopenia is caused by autoimmune disease

  • Pepole with immune thrombocytopenia (ITP) and who had their spleen removed (splenectomy)

  • Transfusion of red blood cells

  • Transfusion of platelets

The ROBINS‐I tool (Stage II): For each study

Specify a target trial specific to the study.

Design

Individually randomised/cluster‐randomised/matched

Participants

People of all ages with a low platelet count who are due to have surgery

Experimental intervention

Prophylactic platelet transfusion prior to surgery

Control intervention

No prophylactic platelet transfusion prior to surgery (placebo or no treatment).

Is your aim for this study...?

□ To assess the effect of initiating intervention (as in an intention‐to‐treat analysis)

□ To assess the effect of initiating and adhering to intervention (as in a per‐protocol analysis)

Specify the outcome

Specify which outcome is being assessed for risk of bias (typically from among those earmarked for the 'Summary of findings' table). Specify whether this is a proposed benefit or harm of intervention.

Specify the numerical result being assessed

In case of multiple alternative analyses being presented, specify the numeric result (e.g. risk ratio (RR) = 1.52 (95% confidence interval (CI) 0.83 to 2.77) and/or a reference (e.g. to a table, figure or paragraph) that uniquely defines the result being assessed.

Preliminary consideration of confounders

Complete a row for each important confounding area

(i) listed in the review protocol; and

(ii) relevant to the setting of this particular study, or which the study authors identified as potentially important.“Important” confounding areas are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of the intervention. “Validity” refers to whether the confounding variable or variables fully measure the area, while “reliability” refers to the precision of the measurement (more measurement error means less reliability).

(i) Confounding areas listed in the review protocol

Confounding area

Measured Variable (s)

Is there evidence that controlling for this variable was unnecessary?*

Is the confounding area measured validly and reliably by this variable (or these variables)?

OPTIONAL: Is adjusting for this variable (alone) expected to favour the experimental or the control group?

Yes / No / No information

Favour intervention / Favour control / No information

(ii) Additional confounding areas relevant to the setting of this particular study, or which the study authors identified as important

Confounding area

Measured Variable (s)

Is there evidence that controlling for this variable was unnecessary?*

Is the confounding area measured validly and reliably by this variable (or these variables)?

OPTIONAL: Is adjusting for this variable (alone) expected to favour the experimental or the control group?

Yes / No / No information

Favour intervention / Favour control / No information

* In the context of a particular study, variables can be demonstrated not to be confounders and so not included in the analysis: (a) if they are not predictive of the outcome; (b) if they are not predictive of intervention; or (c) because adjustment makes no or minimal difference to the estimated effect of the primary parameter. Note that “no statistically significant association” is not the same as “not predictive”.

Preliminary consideration of co‐interventions

Complete a row for each important co‐intervention (i) listed in the review protocol; and (ii) relevant to the setting of this particular study, or which the study authors identified as important.

“Important” co‐interventions are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of the intervention.

(i) Co‐interventions listed in the review protocol

Co‐intervention

Is there evidence that controlling for this co‐intervention was unnecessary (e.g. because it was not administered)?

Is presence of this co‐intervention likely to favour outcomes in the experimental or the control group?

Favour experimental / Favour comparator / No information

Favour experimental / Favour comparator / No information

Favour experimental / Favour comparator / No information

(ii) Additional co‐interventions relevant to the setting of this particular study, or which the study authors identified as important

Co‐intervention

Is there evidence that controlling for this co‐intervention was unnecessary (e.g. because it was not administered)?

Is presence of this co‐intervention likely to favour outcomes in the experimental or the control group?

Favour experimental / Favour comparator / No information

Favour experimental / Favour comparator / No information

Favour experimental / Favour comparator / No information

'Risk of bias' assessment (cohort‐type studies)

Bias domain

Signalling questions

Elaboration

Response options

Bias due to confounding

1.1 Is there potential for confounding of the effect of intervention in this study?

If N or PN to 1.1: the study can be considered to be at low risk of bias due to confounding and no further signalling questions need be considered

In rare situations, such as when studying harms that are very unlikely to be related to factors that influence treatment decisions, no confounding is expected and the study can be considered to be at low risk of bias due to confounding, equivalent to a fully randomised trial.

There is no NI (No information) option for this signalling question.

Y / PY / PN / N

If Y or PY to 1.1:determine whether there is a need to assess time‐varying confounding:

1.2. Was the analysis based on splitting participants’ follow‐up time according to intervention received?

If N or PN, answer questions relating to baseline confounding (1.4 to 1.6)

If Y or PY, proceed to question 1.3.

If participants could switch between intervention groups then associations between intervention and outcome may be biased by time‐varying confounding. This occurs when prognostic factors influence switches between intended interventions.

NA / Y / PY / PN / N / NI

1.3. Were intervention discontinuations or switches likely to be related to factors that are prognostic for the outcome?

If N or PN, answer questions relating to baseline confounding (1.4 to 1.6)

If Y or PY, answer questions relating to both baseline and time‐varying confounding (1.7 and 1.8)

If intervention switches are unrelated to the outcome, for example when the outcome is an unexpected harm, then time‐varying confounding will not be present and only control for baseline confounding is required.

NA / Y / PY / PN / N / NI

Questions relating to baseline confounding only

1.4. Did the authors use an appropriate analysis method that controlled for all the important confounding areas?

Appropriate methods to control for measured confounders include stratification, regression, matching, standardisation, and inverse probability weighting. They may control for individual variables or for the estimated propensity score. Inverse probability weighting is based on a function of the propensity score. Each method depends on the assumption that there is no unmeasured or residual confounding.

NA / Y / PY / PN / N / NI

1.5. If Y or PY to 1.4: Were confounding areas that were controlled for measured validly and reliably by the variables available in this study?

Appropriate control of confounding requires that the variables adjusted for are valid and reliable measures of the confounding domains. For some topics, a list of valid and reliable measures of confounding domains will be specified in the review protocol but for others such a list may not be available. Study authors may cite references to support the use of a particular measure. If authors control for confounding variables with no indication of their validity or reliability pay attention to the subjectivity of the measure. Subjective measures (e.g. based on self‐report) may have lower validity and reliability than objective measures such as lab findings.

NA / Y / PY / PN / N / NI

1.6. Did the authors control for any post‐intervention variables?

Controlling for post‐intervention variables is not appropriate. Controlling for mediating variables estimates the direct effect of intervention and may introduce confounding. Controlling for common effects of intervention and outcome causes bias.

NA / Y / PY / PN / N / NI

Questions relating to baseline and time‐varying confounding

1.7. Did the authors use an appropriate analysis method that adjusted for all the important confounding areas and for time‐varying confounding?

Adjustment for time‐varying confounding is necessary to estimate per‐protocol effects in both randomised trials and NRSI. Appropriate methods include those based on inverse‐probability weighting. Standard regression models that include time‐updated confounders may be problematic if time‐varying confounding is present.

NA / Y / PY / PN / N / NI

1.8. If Y or PY to 1.7: Were confounding areas that were adjusted for measured validly and reliably by the variables available in this study?

See 1.5 above.

NA / Y / PY / PN / N / NI

'Risk of bias' judgement

Low ‐ No confounding expected.

Low / Moderate / Serious / Critical / NI

Moderate ‐ Confounding expected, all known important confounding domains appropriately measured and controlled for;

and

Reliability and validity of measurement of important domains were sufficient, such that we do not expect serious residual confounding.

Serious ‐ At least one known important domain was not appropriately measured, or not controlled for;

or

Reliability or validity of measurement of a important domain was low enough that we expect serious residual confounding.

Critical ‐ Confounding inherently not controllable, or the use of negative controls strongly suggests unmeasured confounding.

Optional: What is the predicted direction of bias due to confounding?

Can the true effect estimate be predicted to be greater or less than the estimated effect in the study because one or more of the important confounding domains was not controlled for? Answering this question will be based on expert knowledge and results in other studies and therefore can only be completed after all of the studies in the body of evidence have been reviewed. Consider the potential effect of each of the unmeasured domains and whether all important confounding domains not controlled for in the analysis would be likely to change the estimate in the same direction, or if one important confounding domain that was not controlled for in the analysis is likely to have a dominant impact.

Favours experimental / Favours comparator / Unpredictable

Bias in selection of participants into the study

2.1. Was selection of participants into the study (or into the analysis) based on participant characteristics observed after the start of intervention?

This domain is concerned only with selection into the study based on participant characteristics observed after the start of intervention. Selection based on characteristics observed before the start of intervention can be addressed by controlling for imbalances between intervention and control groups in baseline characteristics that are prognostic for the outcome (baseline confounding).

Y / PY / PN / N / NI

If N or PN to 2.1: go to 2.4

2.2. If Y or PY to 2.1: Were the post‐intervention variables that influenced selection likely to be associated with intervention

Selection bias occurs when selection is related to an effect of either intervention or a cause of intervention and an effect of either the outcome or a cause of the outcome. Therefore, the result is at risk of selection bias if selection into the study is related to both the intervention and the outcome.

NA / Y / PY / PN / N / NI

2.3 If Y or PY to 2.2: Were the post‐intervention variables that influenced selection likely to be influenced by the outcome or a cause of the outcome?

NA / Y / PY / PN / N / NI

2.4. Do start of follow‐up and start of intervention coincide for most participants?

If participants are not followed from the start of the intervention then a period of follow‐up has been excluded, and individuals who experienced the outcome soon after intervention will be missing from analyses. This problem may occur when prevalent, rather than new (incident), users of the intervention are included in analyses.

Y / PY / PN / N / NI

2.5.If Y or PY to 2.2 and 2.3, or N or PN to 2.4: Were adjustment techniques used that are likely to correct for the presence of selection biases?

It is in principle possible to correct for selection biases, for example by using inverse probability weights to create a pseudo‐population in which the selection bias has been removed, or by modelling the distributions of the missing participants or follow‐up times and outcome events and including them using missing data methodology. However such methods are rarely used and the answer to this question will usually be “No”

NA / Y / PY / PN / N / NI

'Risk of bias' judgement

Low ‐ All participants who would have been eligible for the target trial were included in the study and start of follow‐up and start of intervention coincide for all participants.

Low / Moderate / Serious / Critical / NI

Moderate ‐ Selection into the study may have been related to intervention and outcome, but the authors used appropriate methods to adjust for the selection bias; or Start of follow‐up and start of intervention do not coincide for all participants, but (a) the proportion of participants for which this was the case was too low to induce important bias; (b) the authors used appropriate methods to adjust for the selection bias; or (c) the review authors are confident that the rate (hazard) ratio for the effect of intervention remains constant over time.

Serious ‐ Selection into the study was related to intervention and outcome;

or

Start of follow‐up and start of intervention do not coincide, and a potentially important amount of follow‐up time is missing from analyses, and the rate ratio is not constant over time.

Critical ‐ Selection into the study was strongly related to intervention and outcome;

or

A substantial amount of follow‐up time is likely to be missing from analyses, and the rate ratio is not constant over time.

Optional: What is the predicted direction of bias due to selection of participants into the study?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterised either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias in classification of interventions

3.1 Were intervention groups clearly defined?

A pre‐requisite for an appropriate comparison of interventions is that the interventions are well‐ defined. Ambiguity in the definition may lead to bias in the classification of participants. For individual‐level interventions, criteria for considering individuals to have received each intervention should be clear and explicit, covering issues such as type, setting, dose, frequency, intensity and/or timing of intervention. For population‐level interventions (e.g. measures to control air pollution), the question relates to whether the population is clearly defined, and the answer is likely to be ‘Yes’.

Y / PY / PN / N / NI

3.2 Was the information used to define intervention groups recorded at the start of the intervention?

In general, if information about interventions received is available from sources that could not have been affected by subsequent outcomes, then differential misclassification of intervention status is unlikely. Collection of the information at the time of the intervention makes it easier to avoid such misclassification. For population‐level interventions (e.g. measures to control air pollution), the answer to this question is likely to be ‘Yes’.

Y / PY / PN / N /NI

3.3 Could classification of intervention status have been affected by knowledge of the outcome or risk of the outcome?

Collection of the information at the time of the intervention may not be sufficient to avoid bias. The way in which the data are collected for the purposes of the NRSI should also avoid misclassification.

Y/ PY / PN / N / NI

'Risk of bias' judgement

Low ‐ Intervention status is well‐defined and based solely on information collected at the time of intervention.

Low / Moderate / Serious / Critical / NI

Moderate ‐ Intervention status is well‐defined but some aspects of the assignments of intervention status were determined retrospectively

Serious ‐ Intervention status is not well‐defined, or major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome.

Critical ‐ (Unusual) An extremely high amount of misclassification of intervention status, e.g. because of unusually strong recall biases.

Optional: What is the predicted direction of bias due to measurement of outcomes or interventions?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterised either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias due to departures from intended interventions

4.1. Was the intervention implemented successfully for most participants?

Consider the success of implementation of the intervention in the context of its complexity. Was recommended practice followed by those administering the intervention?

Y / PY / PN / N / NI

If your aim for this study is to assess the effect of initiating and adhering to intervention (as in a per‐protocol analysis), answer questions 4.2 to 4.4

4.2. Did study participants adhere to the assigned intervention regimen?

Lack of adherence to assigned intervention includes cessation of intervention, cross‐overs to the comparator intervention and switches to another active intervention. We distinguish between analyses where:

(1) intervention switches led to follow‐up time being assigned to the new intervention, and

(2) intervention switches (including cessation of intervention) where follow‐up time remained allocated to the original intervention.

(3 ) is addressed under time‐varying confounding, and should not be considered further here.

Consider available information on the proportion of study participants who continued with their assigned intervention throughout follow‐up. Was lack of adherence sufficient to impact the intervention effect estimate?

NA/ Y / PY / PN / N / NI

4.3. Were important co‐interventions balanced across intervention groups?

Consider the co‐interventions that are likely to affect the outcome and to have been administered in the context of this study, based on the preliminary consideration of co‐interventions and available literature. Consider whether these co‐interventions are balanced between intervention groups.

NA/ Y / PY / PN / N / NI

4.4. If N or PN to 4.1, 4.2 or 4.3: Were adjustment techniques used that are likely to correct for these issues?

Such adjustment techniques include inverse‐probability weighting to adjust for censoring at deviation from intended intervention, or inverse probability weighting of marginal structural models to adjust for time‐varying confounding. Specialist advice may be needed to assess studies that used these approaches.

NA / Y / PY / PN / N / NI

'Risk of bias' judgement

Low ‐ No bias due to deviation from the intended intervention is expected, for example if both the intervention and comparator are implemented over a short time period, and subsequent interventions are part of routine medical care, or if the specified comparison relates to initiation of intervention regardless of whether it is continued.

Low / Moderate / Serious / Critical / NI

Moderate ‐ Bias due to deviation from the intended intervention is expected, and switches, co‐interventions, and some problems with intervention fidelity are appropriately measured and adjusted for in the analyses. Alternatively, most (but not all) deviations from intended intervention reflect the natural course of events after initiation of intervention.

Serious ‐ Switches in treatment, co‐interventions, or problems with implementation fidelity are apparent and are not adjusted for in the analyses.

Critical ‐ Substantial deviations from the intended intervention are present and are not adjusted for in the analysis.

Optional: What is the predicted direction of bias due to departures from the intended interventions?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characteris ed either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias due to missing data

5.1 Were there missing outcome data?

This aims to elicit whether the proportion of missing observations is likely to result in missing information that could substantially impact our ability to answer the question being addressed. Guidance will be needed on what is meant by ‘reasonably complete’. One aspect of this is that review authors would ideally try and locate an analysis plan for the study.

Y / PY / PN / N / NI

5.2 Were participants excluded due to missing data on intervention status?

Missing intervention status may be a problem. This requires that the intended study sample is clear, which it may not be in practice.

Y / PY / PN / N / NI

5.3 Were participants excluded due to missing data on other variables needed for the analysis?

This question relates particularly to participants excluded from the analysis because of missing information on confounders that were controlled for in the analysis.

Y / PY / PN / N / NI

5.4 If Y or PY to 5.1, 5.2 or 5.3: Are the proportion of participants and reasons for missing data similar across interventions?

This aims to elicit whether either (i) differential proportion of missing observations or (ii) differences in reasons for missing observations could substantially impact on our ability to answer the question being addressed.

NA / Y / PY / PN / N / NI

5.5 If Y or PY to 5.1, 5.2 or 5.3: Were appropriate statistical methods used to account for missing data?

It is important to assess whether assumptions employed in analyses are clear and plausible. Both content knowledge and statistical expertise will often be required for this. For instance, use of a statistical method such as multiple imputation does not guarantee an appropriate answer. Review authors should seek naïve (complete‐case) analyses for comparison, and clear differences between complete‐case and multiple imputation‐based findings should lead to careful assessment of the validity of the methods used.

NA / Y / PY / PN / N / NI

'Risk of bias' judgement

Low ‐ Data were reasonably complete; or Proportions of and reasons for missing participants were similar across intervention groups; or Analyses that addressed missing data are likely to have removed any risk of bias.

Low / Moderate / Serious / Critical / NI

Moderate ‐ Proportions of missing participants differ across interventions; or Reasons for missingness differ minimally across interventions; and Missing data were not addressed in the analysis.

Serious ‐ Proportions of missing participants differ substantially across interventions; or Reasons for missingness differ substantially across interventions; and Missing data were addressed inappropriately in the analysis; or The nature of the missing data means that the risk of bias cannot be removed through appropriate analysis.

Critical ‐ (Unusual) There were critical differences between interventions in participants with missing data that were not, or could not, be addressed through appropriate analysis.

Optional: What is the predicted direction of bias due to missing data?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterised either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias in measurement of outcomes

6.1 Could the outcome measure have been influenced by knowledge of the intervention received?

Some outcome measures involve negligible assessor judgment, e.g. all‐cause mortality or non‐repeatable automated laboratory assessments. Risk of bias due to measurement of these outcomes would be expected to be low.

Y / PY / PN / N / NI

6.2 Were outcome assessors aware of the intervention received by study participants?

If outcome assessors were blinded to intervention status, the answer to this question would be ‘No’. In other situations, outcome assessors may be unaware of the interventions being received by participants despite there being no active blinding by the study investigators; the answer to this question would then also be ‘No’. In studies where participants report their outcomes themselves, for example in a questionnaire, the outcome assessor is the study participant. In an observational study, the answer to this question will usually be ‘Yes’ when the participants report their outcomes themselves.

Y / PY / PN / N / NI

6.3 Were the methods of outcome assessment comparable across intervention groups?

Comparable assessment methods (i.e. data collection) would involve the same outcome detection methods and thresholds, same time point, same definition, and same measurements

Y / PY / PN / N / NI

6.4 Were any systematic errors in measurement of the outcome related to intervention received?

This question refers to differential misclassification of outcomes. Systematic errors in measuring the outcome, if present, could cause bias if they are related to intervention or to a confounder of the intervention‐outcome relationship. This will usually be due either to outcome assessors being aware of the intervention received or to non‐comparability of outcome assessment methods, but there are examples of differential misclassification arising despite these controls being in place.

Y / PY / PN / N / NI

'Risk of bias' judgement

Low ‐ The methods of outcome assessment were comparable across intervention groups;

and

The outcome measure was unlikely to be influenced by knowledge of the intervention received by study participants (i.e. is objective) or the outcome assessors were unaware of the intervention received by study participants;

and

Any error in measuring the outcome is unrelated to intervention status.

Low / Moderate / Serious / Critical / NI

Moderate ‐ The methods of outcome assessment were comparable across intervention groups;

and

The outcome measure is only minimally influenced by knowledge of the intervention received by study participants;

and

Any error in measuring the outcome is only minimally related to intervention status.

Serious ‐ The methods of outcome assessment were not comparable across intervention groups;

or

The outcome measure was subjective (i.e. likely to be influenced by knowledge of the intervention received by study participants) and was assessed by outcome assessors aware of the intervention received by study participants;

or

Error in measuring the outcome was related to intervention status.

Critical ‐ The methods of outcome assessment were so different that they cannot reasonably be compared across intervention groups.

Optional: What is the predicted direction of bias due to measurement of outcomes?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterised either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias in selection of the reported result

Is the reported effect estimate unlikely to be selected, on the basis of the results, from...

7.1. ... multiple outcome measurements within the outcome domain?

For a specified outcome domain, it is possible to generate multiple effect estimates for different measurements. If multiple measurements were made, but only one or a subset is reported, there is a risk of selective reporting on the basis of results.

Y / PY / PN / N / NI

7.2 ... multiple analyses of the intervention‐outcome relationship?

Because of the limitations of using data from non‐randomised studies for analyses of effectiveness (need to control confounding, substantial missing data, etc), analysts may implement different analytic methods to address these limitations. Examples include unadjusted and adjusted models; use of final value vs change from baseline vs analysis of covariance; different transformations of variables; a continuously scaled outcome converted to categorical data with different cut‐points; different sets of co‐variates used for adjustment; and different analytic strategies for dealing with missing data. Application of such methods generates multiple effect estimates for a specific outcome metric. If the analyst does not pre‐specify the methods to be applied, and multiple estimates are generated but only one or a subset is reported, there is a risk of selective reporting on the basis of results.

Y / PY / PN / N / NI

7.3 ... different subgroups?

Particularly with large cohorts often available from routine data sources, it is possible to generate multiple effect estimates for different subgroups or simply to omit varying proportions of the original cohort. If multiple estimates are generated but only one or a subset is reported, there is a risk of selective reporting on the basis of results.

Y / PY / PN / N / NI

'Risk of bias' judgement

Low ‐ There is clear evidence (usually through examination of a pre‐registered protocol or statistical analysis plan) that all reported results correspond to all intended outcomes, analyses and sub‐cohorts.

Low / Moderate / Serious / Critical / NI

Moderate ‐ The outcome measurements and analyses are consistent with an a priori plan;

or

are clearly defined and both internally and externally consistent;

and

There is no indication of selection of the reported analysis from among multiple analyses;

and

There is no indication of selection of the cohort or subgroups for analysis and reporting on the basis of the results.

Serious ‐ Outcome measurements or analyses are internally or externally inconsistent; or There is a high risk of selective reporting from among multiple analyses; or the cohort or subgroup is selected from a larger study for analysis and appears to be reported on the basis of the results.

Critical ‐ There is evidence or strong suspicion of selective reporting of results, and the unreported results are likely to be substantially different from the reported results.

Optional: What is the predicted direction of bias due to selection of the reported result?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterised either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Overall bias

'Risk of bias' judgement

Low ‐ The study is judged to be at low risk of bias for all domains.

Low / Moderate / Serious / Critical / NI

Moderate ‐ The study is judged to be at low or moderate risk of bias for all domains.

Serious ‐ The study is judged to be at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.

Critical ‐ The study is judged to be at critical risk of bias in at least one domain.

No information ‐ There is no clear indication that the study is at serious or critical risk of bias and there is a lack of information in one or more key domains of bias (a judgement is required for this).

Optional:

What is the overall predicted direction of bias for this outcome?

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable